Page last updated: 2024-11-02

pioglitazone and Myositis, Inclusion Body

pioglitazone has been researched along with Myositis, Inclusion Body in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Myositis, Inclusion Body: Progressive myopathies characterized by the presence of inclusion bodies on muscle biopsy. Sporadic and hereditary forms have been described. The sporadic form is an acquired, adult-onset inflammatory vacuolar myopathy affecting proximal and distal muscles. Familial forms usually begin in childhood and lack inflammatory changes. Both forms feature intracytoplasmic and intranuclear inclusions in muscle tissue. (Adams et al., Principles of Neurology, 6th ed, pp1409-10)

Research Excerpts

ExcerptRelevanceReference
"The sporadic form of inclusion body myositis (IBM) is the most common late-onset myopathy."2.61Sporadic Inclusion Body Myositis: An Acquired Mitochondrial Disease with Extras. ( De Paepe, B, 2019)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
De Paepe, B1

Reviews

1 review available for pioglitazone and Myositis, Inclusion Body

ArticleYear
Sporadic Inclusion Body Myositis: An Acquired Mitochondrial Disease with Extras.
    Biomolecules, 2019, 01-07, Volume: 9, Issue:1

    Topics: Biomarkers; Cytokines; DNA, Mitochondrial; Growth Differentiation Factor 15; Humans; Hypoglycemic Ag

2019